The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Lilly reports Phase 3 CLL results showing Jaypirca matched and improved on Imbruvica across response rates and early progression trends, with safety consistent between treatments.

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) HO Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, ...